作为一种非传统的T细胞亚群，γδT细胞近年来在免疫治疗领域备受欢迎。它们具有非凡的抗肿瘤潜力和临床应用前景。免疫检查点抑制剂（ICIs）在肿瘤患者中具有显著的疗效，自从它们被纳入临床实践以来，成为肿瘤免疫治疗领域的先锋药物。此外，浸润到肿瘤组织中的γδT细胞被发现处于衰竭或无力状态，并在其表面上上调了许多免疫检查点（ICs），表明γδT细胞具有与传统效应T细胞相似的对ICIs的反应能力。研究表明，靶向ICs可以逆转γδT细胞在肿瘤微环境（TME）中的功能失调状态，并通过提高γδT细胞增殖和激活，加强细胞毒性发挥抗肿瘤作用。澄清γδT细胞在TME中的功能状态以及它们与ICs相互作用的机制，将巩固ICIs与γδT细胞联合治疗作为一种良好的治疗选择。©2023.作者（们）.

As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy in recent years. They have extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious in tumor patients, have become pioneer drugs in the field of tumor immunotherapy since they were incorporated into clinical practice. In addition, γδT cells that have infiltrated into tumor tissues are found to be in a state of exhaustion or anergy, and there is upregulation of many immune checkpoints (ICs) on their surface, suggesting that γδT cells have a similar ability to respond to ICIs as traditional effector T cells. Studies have shown that targeting ICs can reverse the dysfunctional state of γδT cells in the tumor microenvironment (TME) and exert antitumor effects by improving γδT-cell proliferation and activation and enhancing cytotoxicity. Clarification of the functional state of γδT cells in the TME and the mechanisms underlying their interaction with ICs will solidify ICIs combined with γδT cells as a good treatment option.© 2023. The Author(s).